Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04054999 · ClinicalTrials.gov registry record · Phase 4
Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT04054999: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT04054999 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04054999, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study will evaluate if Hydroxocobalamin may be a new and possibly superior treatment for refractory vasoplegic syndrome during liver transplant surgery.
Interventions
- DRUG Hydroxocobalamin
- DRUG Methylene Blue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-11-30 |
| Est. Completion | 2024-02-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04054999
The ClinicalTrials.gov registry entry for NCT04054999 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hydroxocobalamin is the first listed.
NCT04054999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04054999 about?
NCT04054999 is a clinical study titled "Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients". This study will evaluate if Hydroxocobalamin may be a new and possibly superior treatment for refractory vasoplegic syndrome during liver transplant surgery.
What is the current status of trial NCT04054999?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2019-11-30. Estimated completion is 2024-02-27.
What interventions are being tested in trial NCT04054999?
The interventions under investigation include: Hydroxocobalamin (DRUG), Methylene Blue (DRUG).
Who is sponsoring clinical trial NCT04054999?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.